Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > LATEST
LATEST
-
BUSINESS Expert Expects New 21-Valent Pneumococcal Shot Capvaxive to Curb Invasive Disease
November 25, 2025
-
REGULATORY Label Updated for Gazyva and Imbruvica: PMDA
November 25, 2025
-
BUSINESS Otsuka’s Hypercholesterolemia Med Nexletol Hits Japan Shelves
November 25, 2025
-
REGULATORY Japan Finalizes Economic Package Positioning Pharma as “Core Industry”
November 25, 2025
-
REGULATORY Local Legislators Urge Routine HPV Shots for Males as LDP Group Renews Push
November 25, 2025
-
REGULATORY Japan to Launch Panel Next Year to Discuss Third-Party Access to Vaccination Database
November 25, 2025
-
REGULATORY Japan to Revise Guidance on Standards for Biological Raw Materials
November 25, 2025
-
REGULATORY Patient Groups Push Back against Delisting OTC-Like Drugs; Panel Leans Toward Higher Copays
November 21, 2025
-
REGULATORY Japan Approves Label Expansions for Braftovi, Augtyro, Uplizna, and More
November 21, 2025
-
REGULATORY Japan Panel OKs NIP Use of Maternal RSV Vaccine from FY2026
November 21, 2025
-
REGULATORY Japan to Add High-Dose Flu Vaccine to NIP for Adults Aged 75 and Over
November 21, 2025
-
BUSINESS Towa, Sawai Log H1 Sales Gains, but Overseas Woes and Litigation Drag on Profit
November 21, 2025
-
BUSINESS 60% of Japan Drug Makers See Lower Operating Profit in H1 FY2025, R&D Costs Weigh on Mid-Sized Firms
November 21, 2025
-
BUSINESS ViiV Japan Pushing Digital Tools to Support Patient-Doctor Communication
November 21, 2025
-
ORGANIZATION Industry Groups Call for More Efficient Clinical Trials in Japan: Joint Statement
November 21, 2025
-
REGULATORY MHLW Panel to Review Kissei’s Uterine Fibroid Drug, 3 More NMEs on December 3
November 21, 2025
-
BUSINESS Japan OKs FoundationOne CDx for Augtyro’s NTRK Fusion Indication
November 21, 2025
-
REGULATORY Ueno Signals Openness to Multiple Approaches on OTC-Like Drug Copays
November 21, 2025
-
REGULATORY LDP Outlines Key Issues for FY2026 Budget, Copay Review for OTC-Like Drugs Included
November 21, 2025
-
REGULATORY Japan to Tap National Anti-Flu Drug Stockpile during Severe Shortages: MHLW
November 21, 2025
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…